The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis
โ Scribed by Chris Braumann; Wolfgang Henke; Christoph A. Jacobi; Wolfgang Dubiel
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- French
- Weight
- 201 KB
- Volume
- 112
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Taurolidine has been successfully used as a disinfectant and to prevent the spreading and growth of tumor cells after surgical excision. However, the underlying mechanisms regarding its effects remain obscure. Here, we show that taurolidine treatment reduces endogenous levels of IฮบBฮฑ, p105, cโJun, p53 and p27 in a doseโdependent manner in colon adenocarcinoma cells, which can be in part due to massive cell death. Because expression of tested proteins was affected by taurolidine, its influence on protein expression was studied. In the coupled transcription/translation system, taurolidine inhibited cโJun expression with an IC~50~ value of 1.4 mM. There was no or little effect on transcription. In contrast, translation of cโJun or p53 mRNA was completely inhibited by taurolidine. To determine which step of translation was affected, prominent complexes occurring in the course of translation were analyzed by density gradient centrifugation. In the presence of taurolidine, no preinitiation translation complex was assembled. Taurolidine also suppressed protein expression in bacteria. Based on our data, we conclude that taurolidine blocks a fundamental early phase of translation, which might explain its effects as a disinfectant and inhibitor of tumor growth. ยฉ 2004 WileyโLiss, Inc.
๐ SIMILAR VOLUMES
## Background: The expression of bcl-2 protein has been related to histopathological features and prognosis in several epithelial tumors. in prostatic adenocarcinoma the prognostic significance of bcl-2 expression is mainly unexplored. ## Methods: The expression of bcl-2 protein was assessed in 2
## Abstract Chromosome rearrangements involving 12q13โ15 are frequent among several tumors, including pleomorphic adenomas. The common molecular target for these aberrations is the __HMGA____2__ gene, but various fusion partners of __HMGA____2__ have been reported in tumors. Here we report the iden